MX2019010981A - Terapias de combinacion para el tratamiento de cancer de mama. - Google Patents
Terapias de combinacion para el tratamiento de cancer de mama.Info
- Publication number
- MX2019010981A MX2019010981A MX2019010981A MX2019010981A MX2019010981A MX 2019010981 A MX2019010981 A MX 2019010981A MX 2019010981 A MX2019010981 A MX 2019010981A MX 2019010981 A MX2019010981 A MX 2019010981A MX 2019010981 A MX2019010981 A MX 2019010981A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- treatment
- combination therapies
- inhibitor
- combination
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 102100038595 Estrogen receptor Human genes 0.000 abstract 1
- 101710196141 Estrogen receptor Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472345P | 2017-03-16 | 2017-03-16 | |
| PCT/US2018/022961 WO2018170447A1 (en) | 2017-03-16 | 2018-03-16 | Combination therapies for the treatment of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010981A true MX2019010981A (es) | 2020-09-07 |
Family
ID=61874039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010981A MX2019010981A (es) | 2017-03-16 | 2018-03-16 | Terapias de combinacion para el tratamiento de cancer de mama. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11083722B2 (enExample) |
| EP (2) | EP3595725B1 (enExample) |
| JP (1) | JP7219224B2 (enExample) |
| KR (1) | KR102517650B1 (enExample) |
| CN (1) | CN110636862A (enExample) |
| AU (1) | AU2018234903B2 (enExample) |
| BR (1) | BR112019019261A2 (enExample) |
| CA (1) | CA3056701A1 (enExample) |
| IL (1) | IL269357B2 (enExample) |
| MA (1) | MA47776A (enExample) |
| MX (1) | MX2019010981A (enExample) |
| RU (1) | RU2764724C2 (enExample) |
| SG (1) | SG11201908531WA (enExample) |
| WO (1) | WO2018170447A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6346368B1 (ja) * | 2016-11-28 | 2018-06-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | インダゾール誘導体の塩及びその結晶 |
| AU2019205821C1 (en) | 2018-01-08 | 2025-02-13 | Pharmacosmos Holding A/S | G1T38 superior dosage regimes |
| EP4240357A1 (en) * | 2020-11-06 | 2023-09-13 | Eisai R&D Management Co., Ltd. | Method of treating breast cancer |
| CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
| WO2024115680A1 (en) | 2022-12-01 | 2024-06-06 | Krka, D.D., Novo Mesto | Ribociclib salts and formulations thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
| IL150638A0 (en) | 2000-01-18 | 2003-02-12 | Aventis Pharma Inc | Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
| DK1252155T3 (da) | 2000-01-18 | 2005-04-04 | Aventis Pharma Inc | Ethanolsolvat af (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-on |
| AU2001287157A1 (en) | 2000-09-12 | 2002-03-26 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| CN101001857B (zh) | 2002-01-22 | 2011-06-22 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| WO2006077424A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| CA2594477C (en) | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| WO2006077425A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| US7776832B2 (en) | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| WO2008001101A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2046330A2 (en) | 2006-07-14 | 2009-04-15 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20090318430A1 (en) | 2006-07-21 | 2009-12-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| LT2632467T (lt) | 2010-10-25 | 2016-09-12 | G1 Therapeutics, Inc. | Cdk inhibitoriai |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| PH12013501940A1 (en) | 2011-03-23 | 2015-12-04 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| RU2015125307A (ru) * | 2012-11-28 | 2017-01-10 | Новартис Аг | Комбинированная терапия |
| US9464092B2 (en) | 2013-03-15 | 2016-10-11 | G1 Therapeutics, Inc. | Transient protection of normal cells during chemotherapy |
| HRP20211879T1 (hr) | 2013-08-14 | 2022-03-04 | Novartis Ag | Kombinirana terapija za liječenje raka |
| CA2940576A1 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
| US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| MX393599B (es) * | 2015-04-29 | 2025-03-19 | Radius Pharmaceuticals Inc | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco |
| MD3302471T2 (ro) * | 2015-05-29 | 2021-12-31 | Eisai R&D Man Co Ltd | Compuși de alchenă tetrasubstituiți și utilizarea acestora |
-
2018
- 2018-03-16 RU RU2019132893A patent/RU2764724C2/ru active
- 2018-03-16 JP JP2019550800A patent/JP7219224B2/ja active Active
- 2018-03-16 KR KR1020197029851A patent/KR102517650B1/ko active Active
- 2018-03-16 AU AU2018234903A patent/AU2018234903B2/en active Active
- 2018-03-16 SG SG11201908531W patent/SG11201908531WA/en unknown
- 2018-03-16 EP EP18715441.4A patent/EP3595725B1/en active Active
- 2018-03-16 MX MX2019010981A patent/MX2019010981A/es unknown
- 2018-03-16 IL IL269357A patent/IL269357B2/en unknown
- 2018-03-16 CA CA3056701A patent/CA3056701A1/en active Pending
- 2018-03-16 US US16/493,931 patent/US11083722B2/en active Active
- 2018-03-16 CN CN201880030008.9A patent/CN110636862A/zh active Pending
- 2018-03-16 EP EP23159590.1A patent/EP4218820A3/en not_active Withdrawn
- 2018-03-16 WO PCT/US2018/022961 patent/WO2018170447A1/en not_active Ceased
- 2018-03-16 MA MA047776A patent/MA47776A/fr unknown
- 2018-03-16 BR BR112019019261-1A patent/BR112019019261A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019019261A2 (pt) | 2020-06-16 |
| RU2764724C2 (ru) | 2022-01-19 |
| EP4218820A3 (en) | 2023-09-20 |
| IL269357A (en) | 2019-11-28 |
| AU2018234903B2 (en) | 2024-02-08 |
| IL269357B1 (en) | 2024-06-01 |
| EP3595725A1 (en) | 2020-01-22 |
| AU2018234903A1 (en) | 2019-10-10 |
| US20210113537A1 (en) | 2021-04-22 |
| US11083722B2 (en) | 2021-08-10 |
| KR20190125448A (ko) | 2019-11-06 |
| JP2020510075A (ja) | 2020-04-02 |
| RU2019132893A3 (enExample) | 2021-06-24 |
| WO2018170447A1 (en) | 2018-09-20 |
| MA47776A (fr) | 2020-01-22 |
| KR102517650B1 (ko) | 2023-04-05 |
| CA3056701A1 (en) | 2018-09-20 |
| IL269357B2 (en) | 2024-10-01 |
| JP7219224B2 (ja) | 2023-02-07 |
| RU2019132893A (ru) | 2021-04-16 |
| EP3595725B1 (en) | 2023-05-03 |
| SG11201908531WA (en) | 2019-10-30 |
| EP4218820A2 (en) | 2023-08-02 |
| CN110636862A (zh) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019384119A8 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| MX2019010981A (es) | Terapias de combinacion para el tratamiento de cancer de mama. | |
| MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
| NZ754865A (en) | Combination therapy for the treatment of cancer | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| MX2018010709A (es) | Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. | |
| MY201580A (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor | |
| MX2019015212A (es) | Compuestos para el tratamiento del sarcoma. | |
| AU201814587S (en) | Ultrasound therapeutic treatment cart | |
| MX2019002115A (es) | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. | |
| PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| MY192385A (en) | Methods of treating acute kidney injury | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| IL304245A (en) | Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment | |
| NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
| MX2018000135A (es) | Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2). | |
| MX2021001764A (es) | Terapia de combinacion. | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. |